NRG Oncology Trial Confirms Radiotherapy as the Preferred Standard of Care Post-Radical Hysterectomy for Early-Stage Intermediate-Risk Cervical Cancer
Results from the recent NRG Oncology GOG-0263 phase III clinical trial have brought significant insights into the treatment protocols for early-stage, intermediate-risk cervical carcinoma. This study examined the effects of incorporating cisplatin-based chemotherapy into a regimen of adjuvant radiotherapy following radical hysterectomy and lymphadenectomy. Remarkably,